FATE vs JBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

FATE

41.0
AI Score
VS
FATE Wins

JBIO

32.5
AI Score

Investment Advisor Scores

FATE

41score
Recommendation
HOLD

JBIO

33score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric FATE JBIO Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 9.2% 0.0% FATE
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 41.0/100 32.5/100 FATE
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY FATE

Relative Price Performance (Last 90 Days)

FATE 1M: -16.9% · 3M: -34.9% JBIO 1M: +17.1% · 3M: -29.3%

Current Technical Phase

FATE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.3%), weak momentum, RSI 36

RSI (14): 35.7 · Price: $1.77

JBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 62

RSI (14): 62.1 · Price: $16.40

Fundamentals Snapshot

Metric FATE JBIO
Market Cap — —
Forward P/E -1.8 -6.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin -12.0% —
Operating Margin -15.0% 0.0%
EPS -1.09 -1.92
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, FATE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.